Innoviva (Nasdaq:INVA) - Stock Price, News & Analysis

INVA Stock Overview

Engages in the development and commercialization of pharmaceutical products in the United States and internationally.

INVA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	2/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 81.1% below our estimate of its fair value

Risk Analysis

Earnings have declined by 12% per year over past 5 years

Profit margins (44%) are lower than last year (80.3%)

Has a high level of debt

Innoviva, Inc. Competitors

Phibro Animal Health

NasdaqGM:PAHC

US$744.9m

SIGA Technologies

NasdaqGM:SIGA

US$631.3m

Ligand Pharmaceuticals

NasdaqGM:LGND

US$1.9b

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.2b

Price History & Performance

Summary of all time highs, changes and price drops for Innoviva
Historical stock prices
Current Share Price	US$18.55
52 Week High	US$19.44
52 Week Low	US$12.22
Beta	0.57
11 Month Change	5.52%
3 Month Change	17.48%
1 Year Change	39.68%
33 Year Change	24.58%
5 Year Change	69.10%
Change since IPO	2.43%

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Jul 26

Recent updates

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Jul 26

Innoviva: Potentially Overvalued

Jun 21

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

Shareholder Returns

	INVA	US Pharmaceuticals	US Market
7D	1.0%	2.3%	3.1%
1Y	39.7%	17.4%	25.4%

Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 17.4% over the past year.

Return vs Market: INVA exceeded the US Market which returned 25.4% over the past year.

Price Volatility

Is INVA's price volatile compared to industry and market?
INVA volatility
INVA Average Weekly Movement	2.8%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Stable Share Price: INVA has not had significant price volatility in the past 3 months.

Volatility Over Time: INVA's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	112	Pavel Raifeld	www.inva.com

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.

Innoviva, Inc. Fundamentals Summary

How do Innoviva's earnings and revenue compare to its market cap?
INVA fundamental statistics
Market cap	US$1.16b
Earnings (TTM)	US$145.42m
Revenue (TTM)	US$330.50m

8.0x

P/E Ratio

3.5x

P/S Ratio

Is INVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INVA income statement (TTM)
Revenue	US$330.50m
Cost of Revenue	US$31.82m
Gross Profit	US$298.68m
Other Expenses	US$153.25m
Earnings	US$145.42m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	2.32
Gross Margin	90.37%
Net Profit Margin	44.00%
Debt/Equity Ratio	77.8%

How did INVA perform over the long term?

See historical performance and comparison

INVA Stock Overview

Rewards

Risk Analysis

Innoviva, Inc. Competitors

NasdaqGM:PAHC

US$744.9m

NasdaqGM:SIGA

US$631.3m

NasdaqGM:LGND

US$1.9b

NasdaqGS:COLL

US$1.2b

Price History & Performance

Recent News & Updates

Price target increased by 20% to US$18.00

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Recent updates

Price target increased by 20% to US$18.00

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Innoviva: Potentially Overvalued

Now 21% undervalued

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Price target decreased by 23% to US$13.00

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 12% to US$15.17

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva Stock? Not Yet. Short Puts? Definitely.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Price target decreased to US$18.67

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Price target increased to US$20.50

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Innoviva Inc.: Short Puts Are Compelling

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Independent Chairman of the Board recently bought US$264k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva reports Q1 results

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations